Results 121 to 130 of about 69,250 (228)

Monocyte maturation pattern by flow cytometry expression of CD64, CD300e, and CD14 correlates to presence of myeloid neoplasm and helps identify blast equivalents in the setting of monocytic neoplasm

Cytometry Part B: Clinical Cytometry, Volume 110, Issue 3, Page 149-159, May 2026.
Abstract CD300e is a marker of mature monocytes in flow cytometry; however, there is limited detailed information on staining patterns in conjunction with other monocyte markers. We evaluated the flow cytometric staining patterns of CD64, CD14, and CD300e in 12 negative and 33 positive peripheral blood specimens and 16 negative and 56 positive bone ...
Jenny Zhang, Jacob Kaplan, Elizabeth Courville   +2 more
wiley   +1 more source

Calculation of MPN and the Development of a Computer Program for MPN Enumeration

Japanese Journal of Food Microbiology, 2017
openaire   +2 more sources

JAK2 V617F mutations and thrombosis in BCR-ABL1 negative myeloproliferative neoplasms: clinical profile and hematologic insights. [PDF]

Leuk Res Rep
Lubis AM, Baskoro MO, Anindyah G, Harahap AS.   +3 more
europepmc   +1 more source

Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathways. [PDF]

Pharm Sci Adv
Liu M, Li Y, Qin C, Wang L, Guo M, Wang Y, Zhou Q, Shi Z, Hao W, Li Y, Zhao B.   +10 more
europepmc   +1 more source

CDK6 inactivation counteracts CALR‐mutant‐induced MPN evolution and sensitizes MPN stem cells to interferon‐α treatment

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Interferon‐α (IFNα) remains a potent therapeutic option for myeloproliferative neoplasms (MPNs) with an activated JAK/STAT signaling axis. However, variable patient responses highlight the need for optimized combination strategies. Recent studies suggest a link between cyclin‐dependent kinase 6 (CDK6) and IFN signaling.
Brian Ringhofer, Wolfram Polzer, Michaela Prchal‐Murphy, Eszter Doma, Sebastian Kollmann, Elisabeth Gamper, Jonatan Kendler, Belinda S. Maw, Eva Zebedin‐Brandl, Juan Li, Anthony R. Green, Maria‐Theresa Krauth, Emir Hadzijusufovic, Daniel Ivanov, Peter Valent, Gregor Hoermann, Thorsten Klampfl, Veronika Sexl, Karoline Kollmann   +18 more
wiley   +1 more source

MPRIP::PDGFRB fusion identified in a male patient with a myeloid/lymphoid neoplasm with eosinophilia. [PDF]

Ann Hematol
Gao M, Bachiashvili K, Jamy O, Harada S, Mackinnon AC, Ravindran A, Chen Y, Carroll AJ, Mikhail FM.   +8 more
europepmc   +1 more source

Thrombosis in Low‐Risk Polycythemia Vera: Insights From a Large Real‐World Cohort

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT Polycythemia vera (PV) is a myeloproliferative neoplasm driven by JAK2 mutations and associated with thrombotic complications. Current risk stratification classifies younger patients without prior thrombosis as low‐risk (LR), yet long‐term outcomes in this group remain poorly defined.
Inbar Cohen, Alon Rozental, Pia Raanani, Adi Shacham Abulafia   +3 more
wiley   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +1 more source

Macrophage‐Targeting Biomaterials for Osteoarthritis Therapy

Journal of Biomedical Materials Research Part A, Volume 114, Issue 5, May 2026.
Macrophage‐Targeting Biomaterials for Osteoarthritis Therapy. Created in BioRender. Jain, E. (2026) https://BioRender.com/x4f9o8g. ABSTRACT Osteoarthritis (OA) is a highly prevalent, disabling, and painful disease of the joints, characterized by progressive cartilage degeneration, synovial fibrosis, and pain.
Era Jain, Paul Nana Kwame Sagoe
wiley   +1 more source

DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations. [PDF]

Ann Hematol
Arafat AMA, Ghaffar HAA, Khallaf AM, Younes SAM, Morad MA, Mahgoub SMA.   +5 more
europepmc   +1 more source